Log in

Relevant bibliographies by topics / Early-stage breast cancer (EBC) / Journal articles

To see the other types of publications on this topic, follow the link: Early-stage breast cancer (EBC).

Journal articles on the topic 'Early-stage breast cancer (EBC)'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Early-stage breast cancer (EBC).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kota, Karthik Joshua, Rekha Gyanchandani, Margaret Quinn Rosenzweig, et al. "cfDNA mutation frequency in early stage breast cancer." Journal of Clinical Oncology 35, no. 15_suppl (2017): e23047-e23047. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e23047.

Full text

Abstract:

e23047 Background: Though 93% of patient present with early stage breast cancer (EBC), metastatic recurrence is expected in 7-13%. To prevent estrogen receptor (ER) positive disease recurrence, endocrine therapy (ET) is given after local disease. ET guidelines recently extended therapy —specifically tamoxifen—from 5 years to 10 based on ATLAS and aTTom. This pilot study used blood samples from women 6 months post-ET to determine cell free DNA (cfDNA) mutation prevalence in disease-free patients Methods: Patients with EBC and continued follow-up after ET were recruited from the Magee Women’s Br

APA, Harvard, Vancouver, ISO, and other styles

2

Skvortsova, Liliya, Saltanat Abdikerim, Kanagat Yergali, et al. "Association of Genetic Markers with the Risk of Early-Onset Breast Cancer in Kazakh Women." Genes 15, no. 1 (2024): 108. http://dx.doi.org/10.3390/genes15010108.

Full text

Abstract:

Breast cancer is a global health problem. It is an age-dependent disease, but cases of early-onset breast cancer (eBC) are gradually increasing. There are many unresolved questions regarding eBC risk factors, mechanisms of development and screening. Only 10% of eBC cases are due to mutations in the BRCA1/BRCA2 genes, and 90% have a more complex genetic background. This poses a significant challenge to timely cancer detection in young women and highlights the need for research and awareness. Therefore, identifying genetic risk factors for eBC is essential to solving these problems. This study r

APA, Harvard, Vancouver, ISO, and other styles

3

Nelson, David R., Jacqueline Brown, Aki Morikawa, and Michael Method. "Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics." PLOS ONE 17, no. 2 (2022): e0264637. http://dx.doi.org/10.1371/journal.pone.0264637.

Full text

Abstract:

Objectives To investigate breast cancer-specific mortality by early breast cancer (EBC; Stages I-IIIC) subtype; incidence of high-risk indicators for recurrence (defined in monarchE trial); and mortality risk difference by those who did/did not meet these criteria. Materials and methods Analyses included patients with initial EBC diagnosis between 2010–2015 from Surveillance, Epidemiology, and End Results (SEER) data (n = 342,149). Cox proportional hazards models and Kaplan-Meier estimates examined mortality among 228,031 patients, by subtype (hormone receptor [HR]-positive [+], human epiderma

APA, Harvard, Vancouver, ISO, and other styles

4

Hosen, MM Arif, Md Dayem Uddin, Ipshita Zerin, et al. "Evaluation of Skeletal Metastases in Different Clinical Stages of Breast Cancer Patients." TAJ: Journal of Teachers Association 30, no. 2 (2018): 47–53. http://dx.doi.org/10.3329/taj.v30i2.39137.

Full text

Abstract:

Background: Breast cancer is a common form of cancer among women globally. Bone is the most common site to which breast cancer metastasizes. Between 30% and 85% of patients with metastatic breast cancer will develop bone metastases during the course of the disease.Objective: To evaluate the pattern and distribution of skeletal metastases in different clinical stages of breast cancer patients by using Tc-99m MDP bone scan.Materials and methods: A retrospective study was conducted on 305 consecutive female breast carcinoma patients referred for bone scan to Institute of Nuclear Medicine and Alli

APA, Harvard, Vancouver, ISO, and other styles

5

Xi, Jing, Cynthia X. Ma, and Joyce O'Shaughnessy. "Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach." JCO Oncology Practice 20, no. 11 (2024): 1460–70. http://dx.doi.org/10.1200/op.24.00274.

Full text

Abstract:

Circulating tumor DNA (ctDNA) refers to DNA fragments released from cancer cells into the bloodstream. Clinical utility of ctDNA in breast cancer has been explored in both metastatic breast cancer (MBC) and early-stage breast cancer (EBC) settings. In MBC, ctDNA can detect therapeutically targetable genomic alterations and has shown great potential in predicting treatment response or resistance. Accumulating data suggest that ctDNA might also have prognostic value in MBC. In EBC, emerging data have shown ctDNA's predictive and/or prognostic value in both neoadjuvant and adjuvant settings. Mini

APA, Harvard, Vancouver, ISO, and other styles

6

Gion, María, José Manuel Pérez-García, Antonio Llombart-Cussac, Miguel Sampayo-Cordero, Javier Cortés, and Andrea Malfettone. "Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects." Therapeutic Advances in Medical Oncology 13 (January 2021): 175883592110595. http://dx.doi.org/10.1177/17588359211059587.

Full text

Abstract:

Drug approval for early-stage breast cancer (EBC) has been historically granted in the context of registration trials based on adequate outcomes such as disease-free survival and overall survival. Improvements in long-term outcomes have made it more difficult to demonstrate the clinical benefit of a new cancer drug in large, randomized, comparative clinical trials. Therefore, the use of surrogate endpoints rather than traditional measures allows for cancer drug trials to proceed with smaller sample sizes and shorter follow-up periods, which reduces drug development time. Among surrogate endpoi

APA, Harvard, Vancouver, ISO, and other styles

7

Franks, Jeffrey, Risha Gidwani, Ene Mercy Enogela, et al. "Survival in the real world: A national analysis of patients treated for early-stage breast cancer." Journal of Clinical Oncology 39, no. 28_suppl (2021): 75. http://dx.doi.org/10.1200/jco.2020.39.28_suppl.75.

Full text

Abstract:

75 Background: Many patient population groups are not proportionally represented in clinical trials, including patients of color, at age extremes, or with comorbidities. It is unclear how treatment outcomes may differ for these patients compared to those well represented in trials. Methods: This retrospective cohort study included women diagnosed with early-stage (I-III) breast cancer (EBC) between 2005-2015 in the CancerLinQ Discovery electronic medical record-based dataset. Patients with comorbidities or concurrent cancer were considered unrepresented in clinical trials. Non-White patients a

APA, Harvard, Vancouver, ISO, and other styles

8

Powis, Melanie, Alejandro Gonzalez, Rinku Sutradhar, et al. "Establishing achievable benchmarks for quality improvement in systemic therapy for early-stage breast cancer." Journal of Clinical Oncology 34, no. 7_suppl (2016): 263. http://dx.doi.org/10.1200/jco.2016.34.7_suppl.263.

Full text

Abstract:

263 Background: Setting realistic targets for performance on quality indicators (QI) is a consistent challenge in quality improvement. The purpose of this study was to utilize administrative data to define achievable targets for QI in the early stage breast cancer (EBC) population in relation to systemic therapy (ST) delivery based on best performers. Methods: Deterministically linked administrative healthcare databases were used to identify EBC cases diagnosed 2006 – 2010 in Ontario, Canada. Panel of previously established QIs for systemic therapy was applied to patients who met eligibility c

APA, Harvard, Vancouver, ISO, and other styles

9

Abdel-Qadir, Husam, Paaladinesh Thavendiranathan, Peter C. Austin, et al. "The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study." JNCI: Journal of the National Cancer Institute 111, no. 8 (2019): 854–62. http://dx.doi.org/10.1093/jnci/djy218.

Full text

Abstract:

AbstractBackgroundData are limited regarding the risk of heart failure (HF) requiring hospital-based care after early stage breast cancer (EBC) and its relationship to other types of cardiovascular disease (CVD).MethodsWe conducted a population-based, retrospective cohort study of EBC patients (diagnosed April 1, 2005–March 31, 2015) matched 1:3 on birth-year to cancer-free control subjects. We identified hospitalizations and emergency department visits for CVD through March 31, 2017. We used cumulative incidence function curves to estimate CVD incidence and cause-specific regression models to

APA, Harvard, Vancouver, ISO, and other styles

10

Fedele, Palma, Assunta Maria Lapolla, Laura Orlando, et al. "Analysis of correlation between weight at diagnosis, weight gain after breast cancer treatment, and recurrence in women with early-stage breast cancer (EBC)." Journal of Clinical Oncology 30, no. 15_suppl (2012): e11001-e11001. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e11001.

Full text

Abstract:

e11001 Background: Overweight at the time of EBC diagnosis has been linked frequently to poorer survival in most studies and some evidence suggests that women who gain weight after breast cancer diagnosis are at increased risk of cancer recurrence and death. Most previous studies on this topic have relied on retrospective chart reviews. The aim of this prospective, observational, single-center study is to determine whether weight at diagnosis and weight gain after EBC treatment can be predictive of BC recurrence. Methods: From December 1990 to January 2012, the study included atotal of 311 EBC

APA, Harvard, Vancouver, ISO, and other styles

11

Gupta, Varsha, Vinit Singh, Naman Sharma, et al. "Risk of non-breast cancer–related mortality in breast cancer and dependence on disease characteristics, treatment, and survival duration." Journal of Clinical Oncology 43, no. 16_suppl (2025): 12041. https://doi.org/10.1200/jco.2025.43.16_suppl.12041.

Full text

Abstract:

12041 Background: Breast Cancer (BC) has seen significant improvement in survival in both early (eBC) and metastatic (mBC) setting. Prolonged survival increases the risk of acquisition of other comorbidities and result in non-BC related mortality (NBCRM). Purpose of this study is to identify the high-risk disease characteristics and trends for NBCRM. Methods: Patients (pts) with BC diagnosed as first primary malignancy between 2010-2019 were identified from 2023 release of SEER 17 database, with follow up till 12/31/2021. Causes of mortality were extracted and categorized as BC related mortali

APA, Harvard, Vancouver, ISO, and other styles

12

Wan, Yin, Xin Gao, Sonam Mehta, Zhixiao Wang, Claudio Faria, and Lee Steven Schwartzberg. "Indirect costs associated with metastatic breast cancer." Journal of Clinical Oncology 30, no. 27_suppl (2012): 74. http://dx.doi.org/10.1200/jco.2012.30.27_suppl.74.

Full text

Abstract:

74 Background: To estimate indirect costs (sick leave [SL]/short-term disability [STDI]) associated with metastatic breast cancer (MBC) compared to early stage breast cancer (EBC)/a general population without cancer (controls). Methods: The MarketScan Health and Productivity Management database (2005-2009) was used. Adult BC patients eligible for employee benefits of sick leave and/or STDI were identified. Difference in SL and STDI days was calculated between MBC patients and their propensity score matched EBC cohort or controls during a 12-month follow-up period. Indirect costs due to SL/ STD

APA, Harvard, Vancouver, ISO, and other styles

13

Reduzzi, Carolina, Serena Di Cosimo, Lorenzo Gerratana, et al. "Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer." Cancers 13, no. 10 (2021): 2356. http://dx.doi.org/10.3390/cancers13102356.

Full text

Abstract:

The clinical relevance of circulating tumor cell clusters (CTC-clusters) in breast cancer (BC) has been mostly studied using the CellSearch®, a marker-dependent method detecting only epithelial-enriched clusters. However, due to epithelial-to-mesenchymal transition, resorting to marker-independent approaches can improve CTC-cluster detection. Blood samples collected from healthy donors and spiked-in with tumor mammospheres, or from BC patients, were processed for CTC-cluster detection with 3 technologies: CellSearch®, CellSieve™ filters, and ScreenCell® filters. In spiked-in samples, the 3 tec

APA, Harvard, Vancouver, ISO, and other styles

14

Fidyk, Erin, Patrick J. Ward, Melissa Estevez, et al. "Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC)." Journal of Clinical Oncology 43, no. 16_suppl (2025): 555. https://doi.org/10.1200/jco.2025.43.16_suppl.555.

Full text

Abstract:

555 Background: Emerging evidence from prospective studies underscores the prognostic potential of ctDNA to inform risk stratification and clinical decision-making in EBC (stage I-III). However, its use and correlation with outcomes in routine clinical practice remains less understood. We describe tumor-informed ctDNA testing trends and the association of test results with recurrence risk among pts with EBC in the rw setting. Methods: Pts with an EBC diagnosis (dx) after 1/1/2018 who had documented HR/HER2 status at initial dx, surgery, and ≥1 commercial ctDNA test in the early stage setting w

APA, Harvard, Vancouver, ISO, and other styles

15

Liu, Jing, Sharyn Hunter, Jiemin Zhu, Regina Lai-Tong Lee, and Sally Wai-Chi Chan. "Decision regret regarding treatments among women with early-stage breast cancer: a systematic review protocol." BMJ Open 12, no. 3 (2022): e058425. http://dx.doi.org/10.1136/bmjopen-2021-058425.

Full text

Abstract:

IntroductionWomen with early-stage breast cancer (EBC) are commonly required to make treatment decisions. Decision regret regarding treatments is an adverse outcome that negatively affects women’s psychological well-being and quality of life. A systematic review will be conducted to synthesise evidence about decision regret among women regarding treatments for EBC. The study will focus on levels of decision regret, what is regretted, and the factors associated with decision regret.Methods and analysisA systematic review will be conducted following the Preferred Reporting Items for Systematic R

APA, Harvard, Vancouver, ISO, and other styles

16

Agostinetto, Elisa, Lieveke Ameye, Samuel Martel, et al. "The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC)." Journal of Clinical Oncology 39, no. 15_suppl (2021): 524. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.524.

Full text

Abstract:

524 Background: PREDICT+ is a widely used, free, online tool based on traditional clinico-pathological features, including HER2, developed to predict individual mortality of EBC pts and to aid clinical decision making for adjuvant therapy. However, its prognostic role in HER2+ EBC pts treated with chemotherapy (CT) and anti-HER2 therapies remains unclear. We aimed to investigate the prognostic performance of PREDICT+ in HER2+ EBC pts enrolled in the ALTTO trial. Methods: ALTTO is a phase III study evaluating adjuvant lapatinib (L) +/- trastuzumab (T) vs. T alone in pts with HER2+ EBC. Pts enro

APA, Harvard, Vancouver, ISO, and other styles

17

Maganini, Robert, Ellis Levine, Kent Hoskins, et al. "Abstract P2-08-26: FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients with Early-Stage Breast Cancer." Clinical Cancer Research 31, no. 12_Supplement (2025): P2–08–26—P2–08–26. https://doi.org/10.1158/1557-3265.sabcs24-p2-08-26.

Full text

Abstract:

Abstract Background: The advent of subtype-specific treatments, particularly hormone therapies and HER2-targeted therapies, has significantly improved survival rates and quality of life for breast cancer (BC) patients. Over the last decade genomic signatures have enabled improved classification of BC into distinct molecular subtypes, providing prognostic and/or predictive information about the metastatic potential of the tumor beyond those of clinicopathologic features. Despite marked progress, BC remains the most frequent cause of cancer death among women globally, accounting for almost 15.5%

APA, Harvard, Vancouver, ISO, and other styles

18

Mahtani, Reshma, Gregory Vidal, Sam Hillman, Ellie John, Simon M. Collin, and Gráinne Long. "Abstract P5-07-24: HER2+ early breast cancer treatment and outcomes by risk of recurrence: a retrospective US electronic health records study." Clinical Cancer Research 31, no. 12_Supplement (2025): P5–07–24—P5–07–24. https://doi.org/10.1158/1557-3265.sabcs24-p5-07-24.

Full text

Abstract:

Abstract Background: Patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) early breast cancer (eBC) remain at risk of relapse despite the use of standard-of-care treatments. We aimed to describe use of neoadjuvant and adjuvant therapies and clinical outcomes by risk of relapse in US pts with eBC since 2011. Methods: This was a retrospective observational study using the nationwide Flatiron Health electronic health record-derived de-identified database. Pts aged ≥18 years with HER2+ eBC (clinical or pathologic stage I, II, or IIIa) who were treated between January 2011

APA, Harvard, Vancouver, ISO, and other styles

19

Duenas, Ashley, Zulikhat Segunmaru, Deborah Collyar, et al. "Abstract P5-10-18: What to measure in Real-World Evidence (RWE) Studies: A Patient Informed Conceptual Disease Model in Early-Stage Breast Cancer." Clinical Cancer Research 31, no. 12_Supplement (2025): P5–10–18—P5–10–18. https://doi.org/10.1158/1557-3265.sabcs24-p5-10-18.

Full text

Abstract:

Abstract Background: The treatment of early-stage breast cancer (eBC) is rapidly evolving, with new advancements in early diagnosis and targeted therapies. Given the heterogeneity of breast cancer, it is crucial to understand specific needs of eBC patients to ensure they are well supported in their treatment journey. Conceptual disease models (CDM) provide a means to organize and visualize concepts of importance for a patient population. A CDM can support real-world studies to understand the multidimensional aspects of eBC and aid in the identification of appropriate patient-reported outcome m

APA, Harvard, Vancouver, ISO, and other styles

20

Perez, Alejandra, Hannah Linden, Nathalie Johnson, et al. "Abstract OT2-05-01: FLEX: 30K Full Transcriptome, Real-World Evidence Database for Early-Stage Breast Cancer, and Investigator-Initiated Protocols." Cancer Research 83, no. 5_Supplement (2023): OT2–05–01—OT2–05–01. http://dx.doi.org/10.1158/1538-7445.sabcs22-ot2-05-01.

Full text

Abstract:

Abstract FLEX: 30K Full Transcriptome, Real-World Evidence Database for Early-Stage Breast Cancer, and Investigator-Initiated Protocols BACKGROUND: Genomic signatures, such as the 70-gene MammaPrint, provide additional prognostic information for early-stage breast cancer (EBC), such as tumor metastatic potential, and expand the available information clinicians and patients require for shared treatment decision making beyond the standard clinicopathologic factors. EBC tumors are further stratified into clinically actionable subtypes by molecular assays such as the 80-gene molecular profiling as

APA, Harvard, Vancouver, ISO, and other styles

21

O'Shaughnessy, Joyce, William Gradishar, Ruth O’Regan, and Vijayakrishna Gadi. "Abstract P2-10-08: Assessment of risk factors for HER2+ breast cancer recurrence: A literature review." Cancer Research 82, no. 4_Supplement (2022): P2–10–08—P2–10–08. http://dx.doi.org/10.1158/1538-7445.sabcs21-p2-10-08.

Full text

Abstract:

Abstract Introduction: Overexpression of HER2 occurs in 15%-20% of early breast cancers (EBC) and is considered more aggressive than other types of breast cancer. Though HER2-targeted therapies have improved patient outcomes, up to 25% of patients will suffer relapse within 10 years, from which the majority of patients will die from incurable metastatic disease. Previous review articles have identified prognostic factors for recurrence for EBC, such as pathological complete response (pCR), hormone receptor (HR) status, and residual cancer burden (RCB). However, most of these were not specific

APA, Harvard, Vancouver, ISO, and other styles

22

Alzahrani, Mashari, Mark Clemons, Lynn Chang, et al. "Management Strategies for Older Patients with Low-Risk Early-Stage Breast Cancer: A Physician Survey." Current Oncology 29, no. 1 (2021): 1–13. http://dx.doi.org/10.3390/curroncol29010001.

Full text

Abstract:

When managing older patients with lower-risk hormone-receptor-positive (HR+), HER2 negative (HER2−) early-stage breast cancer (EBC), the harms and benefits of adjuvant therapies should be taken into consideration. A survey was conducted among Canadian oncologists on the definitions of “low risk” and “older”, practice patterns, and future trial designs. We contacted 254 physicians and 21% completed the survey (50/242). Most respondents (68%, 34/50) agreed with the definition of “low risk” HR+/HER2− EBC being node-negative and either: ≤3 cm and low histological grade, ≤2 cm and intermediate grad

APA, Harvard, Vancouver, ISO, and other styles

23

Soares, Gregório, Allan Pereira, Mariana Vilas Boas, et al. "Value of Systemic Staging in Asymptomatic Early Breast Cancer." Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics 40, no. 07 (2018): 403–9. http://dx.doi.org/10.1055/s-0038-1666997.

Full text

Abstract:

Objective Metastases are rare in early breast cancer (EBC), and international guidelines recommend against routine systemic staging for asymptomatic patients. However, imaging exams remain widely employed in the clinical practice. The aim of the present study is to evaluate the value of imaging for systemic staging in EBC. Methods A retrospective analysis of newly-diagnosed breast cancer (BC) patients was performed. Clinical data including BC subtype, stage, presence of symptoms at diagnosis and instrumental procedures performed for staging were recorded. Results A total of 753 patients were i

APA, Harvard, Vancouver, ISO, and other styles

24

Law, Ernest H., Maria J. Auil, Patricia A. Spears, Kiersten Berg, and Randall Winnette. "Voice Analysis of Cancer Experiences Among Patients With Breast Cancer: VOICE-BC." Journal of Patient Experience 8 (January 2021): 237437352110480. http://dx.doi.org/10.1177/23743735211048058.

Full text

Abstract:

Patient experience literature in early-stage breast cancer (eBC) is limited. This study used a mixed-methods approach to examine patient conversations from public online forums to identify and evaluate eBC-related themes. Among 60,000 eBC-related posts published September 2014–2019, text from a random subset of 15,000 posts was extracted and grouped into linguistically similar, mutually exclusive clusters using an advanced natural language processing (NLP) algorithm. Clusters were characterized using four quantitative metrics: betweenness centrality (linguistic similarity to other areas of the

APA, Harvard, Vancouver, ISO, and other styles

25

Quintyne, Keith Ian, Bernie Woulfe, and Rajnish K. Gupta. "Pre-morbid anthropometric measurement and its impact on outcome in early-stage breast cancer in midwestern Ireland." Journal of Clinical Oncology 31, no. 26_suppl (2013): 45. http://dx.doi.org/10.1200/jco.2013.31.26_suppl.45.

Full text

Abstract:

45 Background: Obesity has become a grave public health concern of global proportions, especially in many developed counties. Clinical obesity may be defined as a body mass indeed (BMI) of greater than or equal to 30kg/m2. Within recent times, growing interest has been seen for the relationship between obesity and cancer; with it being identified as a significant risk factor. It has also been appreciated that it is one of the greatest modifiable risk factors for malignancy. Obesity at the time of diagnosis of early-stage breast cancer (EBC) has been associated with poor outcome, especially bre

APA, Harvard, Vancouver, ISO, and other styles

26

van ’t Veer, Laura J., Elma Meershoek-Klein Kranenbarg, Marjolijn Duijm-de Carpentier, et al. "Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy." JAMA Network Open 7, no. 11 (2024): e2447530. http://dx.doi.org/10.1001/jamanetworkopen.2024.47530.

Full text

Abstract:

ImportanceThere is a need for biomarkers that predict late recurrence risk and extended endocrine therapy (EET) benefit among patients with early-stage breast cancer (EBC). MammaPrint, a 70-gene expression risk-of-recurrence assay, has been found to project significant EET benefit in patients with assay-classified low-risk tumors.ObjectiveTo determine the test’s utility in identifying which patients with EBC in the IDEAL (Investigation on the Duration of Extended Adjuvant Letrozole) trial could benefit from 5-year vs 2.5-year letrozole treatment.Design, Setting, and ParticipantsThis secondary

APA, Harvard, Vancouver, ISO, and other styles

27

Dent, S. F., L. A. Vandermeer, J. N. Spaans, et al. "Adjuvant trastuzumab (T) in early stage breast cancer (EBC): Is cardiac dysfunction (CD) clinically significant?" Journal of Clinical Oncology 25, no. 18_suppl (2007): 11072. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.11072.

Full text

Abstract:

11072 Background: T was funded for women with EBC in Ontario in Aug 05. Clinicians remain concerned about the potential cardiotoxicity of T in women with EBC. The purpose of this retrospective study is to evaluate CD in women with EBC prescribed adjuvant T therapy. Methods: Women with HER2-overexpressing EBC who were initiated on T and chemotherapy (CT) at TOHRCC between Aug 05 and Nov 06 were included in this analysis. A retrospective chart review collected: demographics, CT regimen, T treatment (dose delays, termination of T), CD (defined by the New York Heart Association functional classifi

APA, Harvard, Vancouver, ISO, and other styles

28

Răduţ, Irina Alexandra, Răzvan Stoica, Andreea Ioana Paroşanu, et al. "How to choose the bone modifying treatment for early stage and locally advanced breast cancer?" Romanian Journal of Orthopaedic Surgery and Traumatology 5, no. 1 (2022): 22–27. http://dx.doi.org/10.2478/rojost-2022-0005.

Full text

Abstract:

Abstract Introduction: Breast cancer continues to be the most frequent malignancy in women worldwide. Considerable advances in oncology over the years have led to decreased mortality in early stage (EBC) and locally advanced (ABC) breast cancer, but this has raised concerns about possible long-term effects of anticancer treatment nonetheless. Purpose: The present paper aims to describe the efficacy and safety of osteoclast inhibitors, both as antiresorptive agents, reducing osteoporosis and fracture risk, and as adjuvant anticancer agents, potentially improving disease-related outcomes in pati

APA, Harvard, Vancouver, ISO, and other styles

29

Assi, Hazem I., Ibrahim A. Alameh, Jessica Khoury, et al. "Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients." Journal of Oncology 2020 (November 28, 2020): 1–7. http://dx.doi.org/10.1155/2020/9238084.

Full text

Abstract:

Introduction. Advances in genomic techniques have been valuable in guiding decisions regarding the treatment of early breast cancer (EBC) patients. These multigene assays include Oncotype DX, Prosigna, and Endopredict. There has generally been a tendency to overtreat or undertreat patients, and having reliable prognostic factors could significantly improve rates of appropriate treatment administration. In this study, we showcase the impact of genomic tests on adjuvant treatment decisions in EBC patients. Materials and Methods. This is a retrospective study that includes EBC patients treated be

APA, Harvard, Vancouver, ISO, and other styles

30

Aggarwal, A., A. Vaid, A. Ramesh, et al. "Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling." South Asian Journal of Cancer 07, no. 02 (2018): 096–101. http://dx.doi.org/10.4103/sajc.sajc_110_18.

Full text

Abstract:

AbstractBreast cancer is a heterogeneous disease and patients are managed clinically based on ER, PR, HER2 expression, and key risk factors. The use of gene expression assays for early stage disease is already common practice. These tests have found a place in risk stratifying the heterogeneous group of stage I–II breast cancers for recurrence, for predicting chemotherapy response, and for predicting breast cancer-related mortality. Most guidelines for hormone receptor (HR)–positive early breast cancer recommend addition of adjuvant chemotherapy for most women, leading to overtreatment, which

APA, Harvard, Vancouver, ISO, and other styles

31

Budisavljevic, Anuska, Renata Kelemenic Drazin, and Marina Letica Crepulja. "Abstract P4-01-14: The impact of early breast cancer on psychological resilience, distress levels and perception of health, a longitudinal study." Clinical Cancer Research 31, no. 12_Supplement (2025): P4–01–14—P4–01–14. https://doi.org/10.1158/1557-3265.sabcs24-p4-01-14.

Full text

Abstract:

Abstract Background: Confronting early breast cancer (EBC) diagnosis, along with complex and challenging treatment procedures is an extremely stressful experience. Psychological resilience (PR) is the ability to maintain or restore normal functioning while facing adversity. The aim of this study was to explore the impact of EBC on PR, distress, and perception of health throughout the first year of EBC diagnosis. Study design: The longitudinal case-control study was conducted at the GH Pula, Croatia and approved by the Ethics Committee. Study included 50 patients newly-diagnosed with EBC and 67

APA, Harvard, Vancouver, ISO, and other styles

32

Lipsyc-Sharf, Marla, Cheng Cheng, Arielle J. Medford, et al. "Cadence of circulating tumor DNA (ctDNA) testing for molecular surveillance in early-stage breast cancer (eBC)." Journal of Clinical Oncology 43, no. 16_suppl (2025): 560. https://doi.org/10.1200/jco.2025.43.16_suppl.560.

Full text

Abstract:

560 Background: Post-surgical detection of molecular residual disease (MRD) via plasma ctDNA testing is strongly associated with recurrence of eBC. Our prior real-world data suggests that adjuvant MRD testing impacts clinical care for most patients (pts) with positive ctDNA (ctDNA+) results. Ongoing trials are studying whether adjuvant ctDNA testing improves eBC outcomes. While serial testing is known to improve MRD detection rates, the optimal cadence of testing is unknown. Here, we investigated the role of timing, cadence, and quantitative results of real-world ctDNA testing on detection of

APA, Harvard, Vancouver, ISO, and other styles

33

Yang, Charlie, Raida Khwaja, Patricia Tang, Nancy Nixon, Karen King, and Sasha Lupichuk. "A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab." Current Oncology 29, no. 6 (2022): 4224–34. http://dx.doi.org/10.3390/curroncol29060337.

Full text

Abstract:

The reduced cost of trastuzumab biosimilars has led to increased adoption for HER2-positive breast cancer. This review of trastuzumab biosimilars encompasses this development and real world clinical data in early breast cancer. In addition, we present a retrospective study evaluating the total pathological complete response (tpCR) rates (lack of residual invasive cancer in resected breast tissue and axillary nodes), of MYL-1401O to reference trastuzumab (TRZ) in the neoadjuvant setting for HER2+ early breast cancer (EBC) in Alberta, Canada. Neoadjuvant patients with HER2+ EBC treated with TRZ

APA, Harvard, Vancouver, ISO, and other styles

34

O’Shaughnessy, Joyce, Denise Yardley, Lowell Hart, et al. "Abstract P3-03-12: Risk of recurrence with adjuvant endocrine therapy in real world patients with hormone receptor positive/human epidermal growth factor receptor-negative early breast cancer: a US database analysis." Cancer Research 83, no. 5_Supplement (2023): P3–03–12—P3–03–12. http://dx.doi.org/10.1158/1538-7445.sabcs22-p3-03-12.

Full text

Abstract:

Abstract Background The recommended 5-10 years of adjuvant endocrine therapy (ET) as standard of care has improved outcomes in patients with HR+/HER2− early breast cancer (EBC); however, risk of recurrence persists. The monarchE study demonstrated improvement in invasive disease-free survival (iDFS) with abemaciclib in node-positive, high-risk EBC, the majority of which were stage III (Johnston SRD, et al. J Clin Oncol. 2021;38:3987); however, monarchE’s relatively short follow-up time to date only allowed for observation of early recurrences—longer follow-up is needed to evaluate late recurre

APA, Harvard, Vancouver, ISO, and other styles

35

Friedler, Haley, Meghan Tierney, Melinda Baker, et al. "Abstract PO5-19-04: EVOLVE: An Ambispective, Patient-Centered, Real-World Early-Stage Breast Cancer Study in the United States." Cancer Research 84, no. 9_Supplement (2024): PO5–19–04—PO5–19–04. http://dx.doi.org/10.1158/1538-7445.sabcs23-po5-19-04.

Full text

Abstract:

Abstract Background: While survival for patients with early breast cancer (eBC) has greatly improved with earlier detection and modern treatments, the risk of recurrence and long-term/late treatment-related adverse events (AEs) remain concerns for many patients. Contemporary real-world data are needed to understand current diagnostic pathways, treatment patterns and toxicities, quality of life, and patient experience to better characterize eBC care and knowledge gaps and establish important hypotheses to test in prospective trials, with the ultimate goal to improve both treatment and outcomes

APA, Harvard, Vancouver, ISO, and other styles

36

Wilis Rakhmadhanti and Fef Rukminingsih. "EVALUASI BIAYA KEMOTERAPI PASIEN EARLY BREAST CANCER DI RSUD TUGUREJO SEMARANG PERIODE JULI-DESEMBER 2018." Journal Clinical Pharmacy and Pharmaceutical Science 1, no. 1 (2022): 01–08. http://dx.doi.org/10.61740/jcp2s.v1i1.1.

Full text

Abstract:

Early breast cancer (EBC) is defined as with or without in a breast cancer, but it has not metastasized to wider tissue. Chemotherapy expense has 59% portion of the total cost of cander patients at the hospital. There were 137 EBC patients visit during January-March 2018 conducted at Tugurejo Regional Hospital Semarang. Therefore, research is needed to evaluate the cost of chemotherapy in EBC patient in Tugurejo Hospital Semarang. This study was an observational descriptive study with a cross sectional study design. Data sources were gained from Medical Record (MR) data and billing / billing d

APA, Harvard, Vancouver, ISO, and other styles

37

Dixon-Douglas, Julia, Julie Havas, Federica Giugliano, et al. "Prognostic value of systemic inflammation in early-stage breast cancer in the CANTO cohort (SIM-CANTO)." Journal of Clinical Oncology 43, no. 16_suppl (2025): 566. https://doi.org/10.1200/jco.2025.43.16_suppl.566.

Full text

Abstract:

566 Background: The importance of host anti-tumor immunity in early-stage breast cancer (eBC) is now well recognised. Neutrophil / lymphocyte ratio (NLR) is a peripheral blood-based measure of systemic inflammation and immune status that has been associated with prognosis in other tumour types.We aimed to evaluate the prognostic value of NLR in a large prospective cohort of eBC. Methods: Patients with eBC (stage I-III) in the national French CANTO (NCT01993498) cohort with baseline peripheral blood counts (obtained after diagnosis and before any eBC treatment, including surgery) were included,

APA, Harvard, Vancouver, ISO, and other styles

38

S Mano, Max. "Trastuzumab emtansine: a game changer in HER2-positive early breast cancer." Future Oncology 16, no. 32 (2020): 2595–609. http://dx.doi.org/10.2217/fon-2020-0219.

Full text

Abstract:

Trastuzumab emtansine (T-DM1), given postoperatively for 14 cycles to patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer (EBC) who failed to achieve a pathological complete response after standard chemotherapy and HER2 blockade, represents probably the greatest progress in the management of this aggressive form of breast cancer since the adjuvant trastuzumab pivotal trials. This article addresses the rationale behind the conception of the KATHERINE trial, T-DM1’s structure and pharmacokinetics data, clinical efficacy data of the KATHERINE trial

APA, Harvard, Vancouver, ISO, and other styles

39

Nabulsi, Nadia A., Khatija W. Naing, Huiwen Deng, et al. "Health-related Quality of Life in Hormone Receptor-Positive Early Breast Cancer: Analyses From the Surveillance, Epidemiology, and End Results Medicare Health Outcomes Survey." Journal of Patient Experience 9 (January 2022): 237437352211130. http://dx.doi.org/10.1177/23743735221113058.

Full text

Abstract:

This study describes health-related quality of life (HRQoL) among older Medicare beneficiaries with hormone receptor-positive (HR+) early breast cancer (eBC). Women aged ≥65 years diagnosed with stage I-III HR+ eBC between 1997 and 2014 using the Surveillance, Epidemiology, and End Results Medicare Health Outcomes Survey Data Resource were included. HRQoL was measured using the Short Form Health Survey including physical/mental component summary (PCS/MCS) scores and subscales. Patient surveys ≤ 24 months post-diagnosis were matched to non-cancer controls. Mean differences in HRQoL were compare

APA, Harvard, Vancouver, ISO, and other styles

40

Ackerman, Benjamin, Catherine Keane, Julia A. Beaver, et al. "Trends in diagnosis and treatment of early breast cancer (eBC) in the United States (US) during the COVID-19 era." Journal of Clinical Oncology 39, no. 28_suppl (2021): 227. http://dx.doi.org/10.1200/jco.2020.39.28_suppl.227.

Full text

Abstract:

227 Background: Recent studies have demonstrated a decline in cancer screening and diagnosis during the COVID-19 pandemic. This study explored trends in the diagnosis and management of eBC at a sample of cancer clinics across the US early on in the pandemic. Methods: Patients were selected from the Flatiron Health Research Database (FHRD), an electronic health record-derived de-identified database comprising approximately 280 US cancer clinics (̃800 sites of care). Eligible patients had an ICD code for breast cancer, at least two clinical encounters, and a confirmed eBC (Stage I-III) diagnosis

APA, Harvard, Vancouver, ISO, and other styles

41

Bapna, Ajay, Nidhi Patni, and Sanjeev Patni. "Choosing Wisely – Implication based on Indian data in our patients with breast cancer (INR vs. USD)." International Journal of Molecular & Immuno Oncology 6 (January 8, 2021): 6–10. http://dx.doi.org/10.25259/ijmio_24_2020.

Full text

Abstract:

Objectives: Breast cancer is increasing in India due to aging population, better awareness among general public, willingness to seek treatment of cancers, and easier access to cancers centers. We present our single-center data over a 2-year period and discuss cost implications taking the example of metronomic chemotherapy maintenance and predictive markers in early breast cancer. Material and Methods: Prospectively collected data of all consecutive patients with breast cancer registered between September 2017 and August 2019 were evaluated. Clinical features, stage, receptor status, and other

APA, Harvard, Vancouver, ISO, and other styles

42

Paquet, L., D. A. Frechette, S. F. Dent, X. Song, and S. Verma. "Sexual distress in early breast cancer (EBC) survivors." Journal of Clinical Oncology 28, no. 15_suppl (2010): e19595-e19595. http://dx.doi.org/10.1200/jco.2010.28.15_suppl.e19595.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Gori, Stefania, Alessandra Fabi, Catia Angiolini, et al. "Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE Study." Cancers 15, no. 19 (2023): 4852. http://dx.doi.org/10.3390/cancers15194852.

Full text

Abstract:

To evaluate the rate of early breast cancer (EBC) patients treated with neoadjuvant systemic therapy (NAT) in Italy, criteria of patient selection and types of therapies delivered, an analysis of 1276 patients with stage I-II-III was conducted out of 1633 patients enrolled in the multicenter prospective observational BRIDE study. A total of 177 patients (13.9%) were treated with NAT and 1099 (85.9%) with surgery; in multivariate analysis, menopausal status, cT, cN, grade, HER2-positive and Triple negative (TN) subgroups were significantly associated with the decision to administer NAT. The typ

APA, Harvard, Vancouver, ISO, and other styles

44

Li, Yalun, Tianyi Qian, Hengqiang Zhao, et al. "Decreased level of peripheral CD8+CD28+ T cells is associated with lymph node metastasis in patients with breast cancer." Future Oncology 16, no. 32 (2020): 2611–17. http://dx.doi.org/10.2217/fon-2020-0614.

Full text

Abstract:

Background: Lymph node metastasis (LNM) is an independent risk factor for prognosis in patients with early breast cancer (EBC). Here we explored whether peripheral lymphocyte subtypes could be used as surrogate markers for LNM in patients with EBC. Materials & methods: The lymphocyte subpopulations in peripheral blood were measured in 152 EBC patients and 43 patients with benign breast tumors. Results: The cytotoxic T cell count was significantly lower in patients with EBC than in patients with benign tumors (244.17 ± 105.83 vs 289.97 ± 121.72; p = 0.02), especially in patients with LNM (2

APA, Harvard, Vancouver, ISO, and other styles

45

Dent, Susan Faye, Freya L. Crawley, Nadine A. Graham, and Michelle M. Campbell. "Vascular toxicities of endocrine therapy in early-stage breast cancer: Encouraging observations in a nontrial setting." Journal of Clinical Oncology 30, no. 27_suppl (2012): 68. http://dx.doi.org/10.1200/jco.2012.30.27_suppl.68.

Full text

Abstract:

68 Background: Endocrine therapy (ET) is the standard of care for postmenopausal (PM) women with early stage breast cancer (EBC). Studies suggest higher risk of vascular toxicities (VT) on aromatase inhibitor (AI) therapy. We report incidence/discontinuation rates of VTs in a cardiac clinic. Methods: PM women with hormone receptor positive EBC treated with ET (tamoxifen (T) ± AI) at Ottawa Hospital Cancer Center 01/99-2/06. Data included: demographics, vascular co-morbidities (VCM), ET, duration, VTs. Results: 626 pts, median age 59 years (r: 30-92), median follow-up 98 months (m), stage: I (1

APA, Harvard, Vancouver, ISO, and other styles

46

Lee, Soo Jung, Yee Soo Chae, Yoo Jin Lee, et al. "Association of expression of aquaporin 5 (AQP5) with prognosis in hormone-responsive early breast cancer patients." Journal of Clinical Oncology 31, no. 15_suppl (2013): e11594-e11594. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e11594.

Full text

Abstract:

e11594 Background: Our previous study showed the association of AQP5 up-regulation with cancer proliferation and migration in hormone-responsive breast cancer cell lines (MCF-7) and with unfavorable prognosis in a small number of patients with breast cancer. Accordingly, we analyzed the prognostic impact of AQP5 expression in a number of patients with early breast cancer (EBC). Methods: We enrolled 447 patients who underwent operation for EBC between June 2003 and August 2008 and performed immunohistochemical (IHC) stain for AQP5 expression in tissue microarray (TMA) collected from tumor tissu

APA, Harvard, Vancouver, ISO, and other styles

47

Odzer, Nicole, Rachel Jaber Chehayeb, Maryam Lustberg, Cary P. Gross, and Julia Foldi. "Abstract P2-02-05: Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United States." Cancer Research 83, no. 5_Supplement (2023): P2–02–05—P2–02–05. http://dx.doi.org/10.1158/1538-7445.sabcs22-p2-02-05.

Full text

Abstract:

Abstract Background: The bone modifying agents (BMAs), bisphosphonates, reduce risk of cancer recurrence after diagnosis of early-stage breast cancer (EBC), particularly in postmenopausal women, while another BMA, denosumab, has not been shown to improve EBC outcomes. The 2017 American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) clinical guidelines recommended consideration of adjuvant bisphosphonates for postmenopausal women with EBC who are candidates for adjuvant systemic therapy. Despite this, small survey-based studies suggest that their prescribing is variable. The

APA, Harvard, Vancouver, ISO, and other styles

48

Silva, Diogo J., Gonçalo Miranda, Teresina Amaro, Matilde Salgado, and Alexandra Mesquita. "Prognostic Value of Tumor Budding for Early Breast Cancer." Biomedicines 11, no. 11 (2023): 2906. http://dx.doi.org/10.3390/biomedicines11112906.

Full text

Abstract:

Background: Tumor budding (TB) is a dynamic process associated with the epithelial–mesenchymal transition and a well-established prognostic biomarker for colorectal cancer. As part of the tumor microenvironment, tumor buds demonstrate increased cell motility and invasiveness. Current evidence demonstrates that high levels of TB correlate with disease progression and worst outcomes across different solid tumors. Our work aims to demonstrate the clinical applicability of TB analysis and its utility as a prognostic factor for patients with early breast cancer (EBC). Methods: Retrospective, single

APA, Harvard, Vancouver, ISO, and other styles

49

Stravodimou, A., A. Bodmer, V. Aedo Lopez, J. P. Zurcher, and K. Zaman. "Adjuvant pertuzumab (PER) for HER2-positive early stage breast cancer (eBC): A Swiss experience." European Journal of Cancer 92 (April 2018): S93. http://dx.doi.org/10.1016/s0959-8049(18)30508-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Kamel, Dalia, Veronica Youssef, Wilma M. Hopman, and Mihaela Mates. "Staging Investigations in Asymptomatic Early Breast Cancer Patients at the Cancer Centre of Southeastern Ontario." Current Oncology 28, no. 3 (2021): 2190–98. http://dx.doi.org/10.3390/curroncol28030203.

Full text

Abstract:

Background: In 2012, the American Society for Clinical Oncology (ASCO) identified five key opportunities in oncology to improve patient care, recommending against imaging tests for the staging of patients with early breast cancer (EBC) at low risk for metastases. Similarly, the European Society of Medical Oncology (ESMO) guideline does not support radiological staging in asymptomatic EBC (aEBC). The purpose of this study was to assess local practice and outcomes of staging investigations (SIs) in aEBC at the Cancer Centre of Southeastern Ontario (CCSEO). Methods: A retrospective electronic and

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!